The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Northampton General is one of 5 NHS hospitals taking part in the RAPID-PROTECTION study. A Clinical trial studying antibody treatment combined with COVID-19 vaccination in immunocompromised individuals. Participants will have regular test's including PCR over the course of a year.
The study being funded by Astra Zeneca.
https://www.isrctn.com/ISRCTN53507177
NHS still using Novacyt products
https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/8115-Medical-Single.pdf
"I called it ages ago as another odx and the chart supports that. Obviously i didn’t believe it enough to sell but I called it."
That's because you're Chicken Pi.
LOL
They could double their holding for £650.00
Dr Thomas Heister . Novacyt European Sales Manager at Medica2022
" 2 great days at #Medica! Many good meetings discussing our new CE-IVD diagnostics and RUO solutions #Novacyt has to offer our customers and partners globally. Next week I am flying to Hungary to support our new partner Kromat Ltd. for the last push for this financial year. #moleculardiagnostics #qpcr #Winterplex CE-IVD, #PathFlow, # Kromat Ltd."
https://twitter.com/KilkennyTed/status/1592832862545666048?s=20&t=ksnOC7V2k1H5N4NRjs36Tw
Antonio Argenio
"Great opportunity to talk through our Novacyt VersaLab with Deputy Director for Health and Food Safety - Martin Seychell from the European Commission, we had a chat about the need for remote testing solutions and I look forward to catch up further after #Aidex "
Apparently the new extraction system on show is demo model. The product is in final stages of validation for launch very soon.
https://twitter.com/kilkennyted/status/1592558609845858304?s=61&t=aPQ-59-gib65XmISMIa62g
On the stand is Another new product (Co-Prep extraction machine) that hasn't been launched properly. Will include the LFT reader & Co-Prep liquid handler in failed product launches. The company obviously think it isn't material enough to advise the market or shareholders alike.
https://uk.yahoo.com/news/why-pi-next-covid-variant-132245328.html
Wilson. 547 standard assays listed in the excel file being discontinued. (which was created in June, so not sure why this wasn't mentioned in half year presentation). Not sure how much this will impact the customer base as quite a lot are duplicated with easy or advanced assays. So they haven't ceased production, just rationalized it. https://novacyt.com/products-and-solutions/
https://novacyt.com/novacyt-partners-with-applied-microarrays-in-assay-design/
Working together since 2018.
Exmex. I wonder how Primer Designs work with Applied Microarrays is going.
AMI is a company headquartered in Tempe, AZ, which designs, optimises and manufactures DNA and protein biosensors, and other microarrays on glass, plastic and semiconductors.
Novacyt SA
("Novacyt", the "Company" or the "Group")
UK CTDA Regulatory Approval of genesig ® SARS-CoV-2 Winterplex ® 3 -Gene Test Panel
A multiplex PCR test for the detection of winter viruses, including the
SARS-CoV-2, influenza A and B, and RSV
Paris, France and Camberley, UK - October 26, 2022 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its genesig ® Real-Time PCR SARS-CoV-2 Winterplex test panel ® 3G (Winterplex ® 3G) has been approved in the UK by the UK Health Safety Agency (Coronavirus Test Device Approvals) (Amendment) ("CTDA") Regulations 2021, becoming the company's sixth PCR test to be added to the CTDA Registry of Approved COVID-19 Diagnostic Products .
Winterplex ® 3G is a high-throughput multiplex screening test (with 96 reactions per kit) for the detection of influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 (COVID-
(especially the detection of ORF1ab, S and M gene targets) from oropharyngeal, nasopharyngeal or saliva samples.
This approval comes ahead of winter virus season in the northern hemisphere and means the company can now sell Winterplex® 3G in the UK. The Winterplex® 3G enables healthcare systems to differentiate between common respiratory infections that present with similar symptoms. Faced with the spread of winter viruses, Novacyt continues to monitor all strains of influenza A, influenza B, RSV and SARS-CoV-2 through its bioinformatics monitoring program.
David Allmond, CEO of Novacyt Group, commented:
“We are proud that Winterplex® 3G has been approved under UK CTDA regulations. This product is a combined test which offers the advantage of testing several seasonal viruses at the same time, saving time and requiring only a single patient sample We believe this is important as the diagnostics market tends to favor respiratory panels over COVID-19 specific tests due to concerns about the parallel increase in COVID-19 cases and flu this winter. This latest approval positions us well with our consolidated COVID-19 portfolio for potential future outbreaks.as we continue to focus on our expanded respiratory product offering as part of our growth strategy."
The status of applications currently submitted to the CTDA by the Company is as follows:
#
Product Name
Current CTDA Status
1
genesig® COVID -19Real-Time PCR
Approved November 2021
2
PROmate® COVID -19 2G (q32)
Approved February 2022
3
PROmate® COVID -19 1G (q32)
Approved in April 2022
4
PROmate® COVID -19 1G (q16)
Approved May 2022
5
exsig™ COVID-19 Direct
Approved July 2022
6
genesig ® Real-time PCR SARS-CoV-2 Winterplex
Approved October 20, 2022
7
genesig ® COVID-19 3G Real-Time PCR
8
PathFlow® COVID -19 Rapid Antigen Pro
Evaluation in progress
9
PathFlow® COVID -19 Rapid Antigen Self-Test
- End -
Rns in morning
What Is Tata Medical and Diagnostics?
Tata Medical and Diagnostics (Tata MD) aims to provide leading-edge, patient-centric solutions, with a clear vision to make healthcare accessible and reliable. Tata Medical and Diagnostics Ltd (Tata MD) is a new healthcare venture from the Tata group, India’s largest business conglomerate. Tata MD aims to provide leading-edge, patient-centric solutions, with a clear vision to make healthcare access more accessible and reliable. Tata MD’s products and solutions will span different facets of a fast-evolving healthcare economy including the launch CRISPR based innovative diagnostics, state-of-the-art medical devices as well as integrated ‘connected care’ solutions for rural and urban consumers. Our vision is to be a trusted, long-term partner and help shape the evolution of healthcare towards more inclusive and integrated patient-centric solutions that are delivered to consumers using the innovative hybrid ‘Bridgital’ model. By investing in robust partnerships and collaborative frameworks with global industry leaders and research organizations, Tata MD will help build world-class science and technical capabilities as well as drive use of digital technologies to ensure “connected care” for patients. As a company launched during the 2020 pandemic, one defining priority for Tata MD was to develop, launch and scale the availability of affordable diagnostics to treat COVID-19. Our first product is the world’s first commercially available CRISPR Cas-9 based COVID-19 test. It is powered by FELUDA from CSIR-IGIB, a leading Indian biosciences research institute, and will be the new standard for COVID-19 diagnostics. In the future, Tata MD CHECK diagnostics will be extended to other diseases and medical applications as a comprehensive diagnostic tool.
Company formed during the Pandemic (2020) .
Tata Medical and Diagnostics's estimated annual revenue is currently $27M per year.
Tata Medical and Diagnostics has 215 Employees.
Tata Medical and Diagnostics grew their employee count by 481% last year.
http://mygopcr.com/mygopro/userguide/mygopro-user-guide-v3-en-web.pdf
Welsh
Take a look at these links for the user guides and make up your own mind.
Novacyt instrument
http://www.mygopcr.com/mygopro/userguide/mygopro-user-guide-v3-en-web.pdf
Tata MD instrument
https://tatamd.com/sites/default/files/2021-12/ExpressPCR-User-Guide-2022.pdf
"I post for myself - not for others. i could easily post a super popular post on here - if i was chasing likes. but i am not."
You might believe that Swag but nearly 7000 post's indicates you are looking to influence some. And whether it be Novacyt , Omega or any other co. All your posts have a negative slant. Why is that?